Connaught Laboratories Limited

Aventis Pasteur Limited

Other

University of Alberta

Merial Limited

Sanofi Pasteur Inc.

Sheena M Loosmore

Michel Henri Klein

Yan-Ping Yang

Pele Chong

Raymond P Oomen

Robin E Harkness

Anthony Bernard Schryvers

Gavin Ross Zealey

Stephen A Cockle

Andrew D Murdin

Scott Gray-Owen

Reza Khayyam Yacoob

Run-Pan Du

Heather A Boux

Glen D Armstrong

Randy J Read

Bart Hazes

Ken Sasaki

Penelope E Stein

Jean-Christophe Francis Audonnet

Lisa E Myers

Michel H Klein

Yan Ping Yang

Wayne Thomas

Jules Maarten Minke

Quijun Wang

Jiansheng Yao

Marvin J Grubman

Dwo Yuan Sia

Gavin Zealey

Dw&oslash; Yuan Charles Sia

Robert Nordgren

Dwe Yuan Sia

An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.

Recombinant vaccine against West Nile Virus

The present invention relates to chimeric vectors. More specifically, the invention relates to recombinant poxvirus vectors and viruses that are capable of expressing an alphaviral RNA replicon expressing a heterologous sequence of interest.

Chimeric vectors

Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of, is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type calso are described.

[object Object]

The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant avipox that expresses gene products of foot and mouth disease virus (FMDV), and to compositions or vaccines that elicit immune responses directed to FMDV gene products and which can confer protective immunity against infection by FMDV.

Avipox recombinants expressing foot and mouth disease virus genes

Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins ofstrains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain offree of other proteins of thestrain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.

Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain ofor a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Transferrin receptor genes

Expression vectors are described which permit the recombinant expression of proteins which essentially contain, in addition to nucleic acid encoding the recombinant protein, nucleic acid encoding a non-proteolytic analog ofHin47 protein, with or without leader sequence, or nucleic acid encoding high molecular weight proteins of non-typeable, which are hmwB, hmwC or hmwBC.

Co-expression of recombination proteins

A multi-component immunogenic composition confers protection on an immunized host against infection caused by. Such composition comprises at least two different antigens of, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeableenhance the immune response in a host to a non-proteolytic analog of Hin47 protein in such immunogenic compositions with one component not impairing the immunogenicity of the other. Thevaccine may be combined with DTP component vaccines to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.

Protective high molecular weight (HMW) proteins are produced recombinantly by expression fromby using a promoter effective inand a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including thecer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeablestrain have been identified.

Protective recombinant Haemophilus influenzae high molecular weight proteins

An isolated and purified outer membrane protein of a Moraxella strain, particularly , having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

High molecular weight major outer membrane protein of moraxella

An isolated and purified outer membrane protein of a Moraxella strain, particularly , has a molecular mass of about 200 kDa. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

An isolated and purified outer membrane protein of a Moraxella strain, particularly having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful in diagnostic applications and immunogenic compositions, particularly for in vivo administration to a host to confer protection against disease caused by a bacterial pathogen that produces the about 200 kDa outer membrane protein or produces a protein capable of inducing antibodies in a host specifically reactive with the about 200 kDa outer membrane protein.

Purified and isolated nucleic acid molecules are provided which encode transferrin receptor proteins of Moraxella, such as or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce recombinant transferrin receptor proteins Tbp1 and Tbp2 of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection.

Growing community of inventors

Aurora, Canada

Sheena M Loosmore